Benkelfat C, Poirier M F, Léouffre P, Gay C, Löo H
Can J Psychiatry. 1987 Apr;32(3):175-8. doi: 10.1177/070674378703200303.
After 1 mg DST, 25 major depressive patients (DSM-III) received at random either a specific inhibitor of noradrenaline reuptake (Maprotiline) or an inhibitor of serotonin reuptake (Indalpine or Citalopram). After at least 3 weeks of treatment, no difference was found in treatment response between suppressors and non suppressors. This study is unable to confirm the usefulness of the DST in selection of treatment according to its central activity on serotonin or noradrenaline-reuptake.
对25名重度抑郁症患者(依据《精神疾病诊断与统计手册》第三版)给予1毫克地塞米松抑制试验(DST)后,随机给予他们去甲肾上腺素再摄取特异性抑制剂(马普替林)或血清素再摄取抑制剂(茚达品或西酞普兰)。经过至少3周的治疗后,发现抑制者与非抑制者在治疗反应上没有差异。这项研究无法证实DST根据其对血清素或去甲肾上腺素再摄取的中枢活性在治疗选择中的有用性。